新型CRISPR-Cas12L酶和系统

By developing a novel CRISPR/Cas system constructed using RNA-guided endonucleases, the limitations of existing systems have been overcome, enabling more robust gene editing capabilities suitable for multiplex gene editing.

CN113930410BActive Publication Date: 2026-07-17CHINA AGRI UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CHINA AGRI UNIV
Filing Date
2020-06-29
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing CRISPR/Cas systems each have their own advantages and disadvantages, and there is a lack of a more robust gene editing technology with good performance in many aspects.

Method used

A novel RNA-guided endonuclease was developed, and a new CRISPR/Cas system, including proteins, conjugates, and complexes, was constructed based on this enzyme for nucleic acid editing at specific sites.

Benefits of technology

This provides a more robust CRISPR/Cas system that can bind to and cleave target sequences at specific sites under the guidance of guide RNA, exhibiting highly efficient nucleic acid editing capabilities and suitable for multiplex gene editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002560394800000261
    Figure BDA0002560394800000261
  • Figure BDA0002560394800000271
    Figure BDA0002560394800000271
  • Figure BDA0002560394800000281
    Figure BDA0002560394800000281
Patent Text Reader

Abstract

本发明涉及核酸编辑领域，特别是规律成簇的间隔短回文重复(CRISPR)技术领域。具体而言，本发明涉及Cas效应蛋白，包含此类蛋白的融合蛋白，以及编码它们的核酸分子。本发明还涉及用于核酸编辑(例如，基因或基因组编辑)的复合物和组合物，其包含本发明的蛋白或融合蛋白，或编码它们的核酸分子。本发明还涉及用于核酸编辑(例如，基因或基因组编辑)的方法，其使用包含本发明的蛋白或融合蛋白。
Need to check novelty before this filing date? Find Prior Art